2 Weight reduction by menopause status A pooled, post hoc analysis of the OASIS 4 and STEP trials showed that regardless of menopause stage, use of semaglutide was associated with significant weight loss
1997;272(5):2936-2941.[DOI] 11
This helps check how well the body tolerates berberine
Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Bevacizumab was the first anti-angiogenic drug used in patients with RCC, followed by VEGFR inhibitors such as sunitinib, sorafenib, pazopanib, cabozantinib, and axitinib (101)
